Gilead Rises 0.79% Despite 36.48% Volume Drop and 234th Rank Amid Pheton's Denial of Acquisition Rumors

Gilead Sciences (GILD) rose 0.79% on August 1, 2025, with a trading volume of $570 million, representing a 36.48% decline from the previous day’s volume and ranking 234th in market activity. The stock’s modest gain occurred amid market uncertainty following a denial from Pheton Holdings (PTHL) regarding unconfirmed acquisition rumors involving Gilead.

Pheton Holdings, a Beijing-based healthcare solutions provider, categorically dismissed speculation about a potential Gilead acquisition as “false” and “fabricated,” attributing its recent share price volatility to a speculative article by an external platform. While Pheton’s stock plummeted, Gilead’s shares edged higher, suggesting limited immediate impact from the rumor. The company emphasized it had no prior contact with Gilead and plans to collaborate with Nasdaq and regulators to address misinformation. This response underscores the sensitivity of biopharmaceutical stocks to sector-specific news and the broader market’s focus on corporate governance.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day generated a 166.71% return from 2022 to the present, significantly outperforming the benchmark’s 29.18% return. This highlights the influence of liquidity concentration on short-term price movements, particularly for volume-sensitive equities.